An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping

BackgroundGene expression connectivity mapping has gained much popularity in recent years with a number of successful applications in biomedical research testifying its utility and promise. A major application of connectivity mapping is the identification of small molecule compounds capable of inhibiting a disease state. In this study, we are additionally interested in small molecule compounds that may enhance a disease state or increase the risk of developing that disease. Using breast cancer as a case study, we aim to develop and test a methodology for identifying commonly prescribed drugs that may have a suppressing or inducing effect on the target disease (breast cancer).ResultsWe obtained from public data repositories a collection of breast cancer gene expression datasets with over 7000 patients. An integrated meta-analysis approach to gene expression connectivity mapping was developed, which involved unified processing and normalization of raw gene expression data, systematic removal of batch effects, and multiple runs of balanced sampling for differential expression analysis. Differentially expressed genes stringently selected were used to construct multiple non-joint gene signatures representing the same biological state. Remarkably these non-joint gene signatures retrieved from connectivity mapping separate lists of candidate drugs with significant overlaps, providing high confidence in their predicted effects on breast cancers. Of particular note, among the top 26 compounds identified as inversely connected to the breast cancer gene signatures, 14 of them are known anti-cancer drugs.ConclusionsA few candidate drugs with potential to enhance breast cancer or increase the risk of the disease were also identified; further investigation on a large population is required to firmly establish their effects on breast cancer risks. This work thus provides a novel approach and an applicable example for identifying medications with potential to alter cancer risks through gene expression connectivity mapping.

[1]  B. Leyland-Jones,et al.  Biochemistry of azacitidine: a review. , 1987, Cancer treatment reports.

[2]  Jung-Hsin Lin,et al.  Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate. , 2010, Biochemical and biophysical research communications.

[3]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[4]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[5]  Sajjad Karim,et al.  Low expression of leptin and its association with breast cancer: A transcriptomic study , 2016, Oncology reports.

[6]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[7]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[8]  K. Rahmouni,et al.  The cellular and molecular bases of leptin and ghrelin resistance in obesity , 2017, Nature Reviews Endocrinology.

[9]  Qing Wen,et al.  A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping , 2016, BMC Bioinformatics.

[10]  Peter Bankhead,et al.  QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics , 2016, BMC Bioinformatics.

[11]  Jianmin Si,et al.  COL11A1 is overexpressed in gastric cancer tissues and regulates proliferation, migration and invasion of HGC-27 gastric cancer cells in vitro. , 2017, Oncology reports.

[12]  Mark A. Ragan,et al.  Breast cancer classification: linking molecular mechanisms to disease prognosis , 2015, Briefings Bioinform..

[13]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[14]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[15]  M. Kane,et al.  Analysis, occurrence, and function of 9-cis-retinoic acid. , 2012, Biochimica et biophysica acta.

[16]  Philip R Quinlan,et al.  Histological evaluation of AMPK signalling in primary breast cancer , 2009, BMC Cancer.

[17]  C. Chelala,et al.  Gene expression profiling of breast cancer in Lebanese women , 2016, Scientific Reports.

[18]  Shu-Dong Zhang,et al.  Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping , 2011, PloS one.

[19]  D. A. Gorard,et al.  Escalating polypharmacy. Commentary , 2006 .

[20]  Shu-Dong Zhang,et al.  A simple and robust method for connecting small-molecule drugs using gene-expression signatures , 2008, BMC Bioinformatics.

[21]  C. Perou,et al.  How many etiological subtypes of breast cancer: two, three, four, or more? , 2014, Journal of the National Cancer Institute.

[22]  D A Gorard,et al.  Escalating polypharmacy. , 2006, QJM : monthly journal of the Association of Physicians.

[23]  Philippe Trechot,et al.  Targeting solid tumours with potassium channel activators. A return to fundamentals? , 2014, Therapie.

[24]  Robert Gentleman,et al.  Querying Genomic Databases: Refining the Connectivity Map , 2012, Statistical applications in genetics and molecular biology.

[25]  R. Dinarvand,et al.  A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis , 2013, Cancer Chemotherapy and Pharmacology.

[26]  B Rachet,et al.  Survival from cancer of the breast in women in England and Wales up to 2001 , 2008, British Journal of Cancer.

[27]  Laura M'Rabet,et al.  Dihomo‐γ‐linolenic acid inhibits tumour necrosis factor‐α production by human leucocytes independently of cyclooxygenase activity , 2003, Immunology.

[28]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[29]  Yi Zhang,et al.  Prognostic significance of PLIN1 expression in human breast cancer , 2016, Oncotarget.

[30]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[31]  J. Brtko,et al.  Proteomic analysis of changes in the protein composition of MCF-7 human breast cancer cells induced by all-trans retinoic acid, 9-cis retinoic acid, and their combination. , 2015, Toxicology letters.

[32]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[33]  Changhong Miao,et al.  COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. , 2016, Oncology reports.

[34]  Mansoor Abdul,et al.  Expression and activity of potassium ion channels in human prostate cancer. , 2002, Cancer letters.

[35]  Kenji Ishimoto,et al.  The Role of PPARs in Cancer , 2008, PPAR research.

[36]  Dong-Sup Lee,et al.  9-Cis-retinoic acid induces growth inhibition in retinoid-sensitive breast cancer and sea urchin embryonic cells via retinoid X receptor α and replication factor C3. , 2012, Molecular endocrinology.

[37]  Navindra Persaud,et al.  Should doxylamine-pyridoxine be used for nausea and vomiting of pregnancy? , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[38]  M. Young,et al.  Targeting AMPK for cancer prevention and treatment , 2015, Oncotarget.

[39]  Qing Wen,et al.  Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies , 2015, BMC Systems Biology.

[40]  Mansoor Abdul,et al.  Activity of potassium channel-blockers in breast cancer. , 2003, Anticancer research.

[41]  Shu-Dong Zhang,et al.  Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia , 2015, Oncotarget.

[42]  Shu-Dong Zhang,et al.  sscMap: An extensible Java application for connecting small-molecule drugs using gene-expression signatures , 2009, BMC Bioinformatics.

[43]  D. Hardie,et al.  Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? , 2015, Clinical Cancer Research.

[44]  J Brtko,et al.  Effects of retinoic acid isomers on proteomic pattern in human breast cancer MCF-7 cell line. , 2013, Endocrine regulations.

[45]  D. Kuik,et al.  Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. , 2002, American journal of obstetrics and gynecology.

[46]  Peter T. Simpson,et al.  Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression , 2012, Breast Cancer Research and Treatment.

[47]  Guillermo Garcia-Manero,et al.  Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. , 2015, The oncologist.

[48]  Joanne L. Wallace,et al.  The Life and Death of Breast Cancer Cells: Proposing a Role for the Effects of Phytoestrogens on Potassium Channels , 2011, The Journal of Membrane Biology.

[49]  Mark A. Ragan,et al.  Breast cancer classification: linking molecular mechanisms to disease prognosis , 2015, Briefings Bioinform..

[50]  L H Li,et al.  Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. , 1970, Cancer research.

[51]  Sujoy Ray,et al.  Oral evening primrose oil and borage oil for eczema. , 2013, The Cochrane database of systematic reviews.

[52]  Shu-Dong Zhang,et al.  Towards Accurate Estimation of the Proportion of True Null Hypotheses in Multiple Testing , 2011, PloS one.

[53]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[54]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[55]  Y. Chen,et al.  PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy , 2012, Cancer Chemotherapy and Pharmacology.

[56]  Guy Sauvageau,et al.  Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene‐Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia , 2013, Stem cells.

[57]  David Carling,et al.  AMPK signalling in health and disease. , 2017, Current opinion in cell biology.

[58]  Nidhal Ben Amor,et al.  TNF-α and its inhibitors in cancer , 2010, Medical oncology.

[59]  J. Neradil,et al.  New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. , 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[60]  R. Ali,et al.  The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: study protocol for a randomized controlled trial , 2011, Trials.